Eli Lilly Reports Results of Lartruvo (olaratumab) in ANNOUNCE P-III Study for Advanced or Metastatic Soft Tissue Sarcoma (STS)

 Eli Lilly Reports Results of Lartruvo (olaratumab) in ANNOUNCE P-III Study for Advanced or Metastatic Soft Tissue Sarcoma (STS)

Eli Lilly Reports Results of Lartruvo (olaratumab) in ANNOUNCE P-III Study for Advanced or Metastatic Soft Tissue Sarcoma (STS)

Shots:

  • The P-III ANNOUNCE study involves assessing of Lartruvo + doxorubicin following lartruvo monothx vs doxorubicin + PBO following PBO monothx in patients with advanced or metastatic STS
  • The study didn’t meet 1EP as OS showing no difference in survival rate with no safety signals observed; AEs (all grades; grade 3-4) fatigue (69%,9% vs 3% 69%); musculoskeletal pain (64%, 8% vs 25%, 2%); decreased appetite (31%, 2% vs 20%, 0%); lymphopenia (77%, 44% vs 73%, 37%); hypokalemia (21%, 8% vs 15%, 3%)
  • Lartruvo (olaratumab) is a platelet-derived growth factor receptor alpha (PDGFR-α) mAb used for blocking PDGFR-α and prevents receptor activation, indicated for soft tissue sarcoma (STS) in combination with doxorubicin

Click here to read full press release/ article | Ref: Eli Lilly | Image:GMP news

 

 

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post